Dr. Jerry Tan

Dermatologist, Windsor, ON

Dr. Tan received his medical degree from Queen’s University in Kingston, Ontario and trained in internal medicine at the University of Toronto and in dermatology at University of British Columbia and University of Michigan. His general dermatology and aesthetic dermatology practices are in Windsor Ontario Canada. He conducts clinical trials research at Windsor Clinical Research, a clinical trials site in dermatology. Aside from industry grants, he has received research funding from the Canadian Dermatology Foundation and the National Institutes of Health Research.

Research focus includes acne, acne scars and rosacea. Additional interests include outcome measurements and informed shared decision making in dermatology. We have developed 3 patient decision aids in dermatology – acne, psoriasis and hidradenitis suppurativa – available at www.informed-decisions.org

Dr. Tan chairs the working group on clinical practice guidelines of the Canadian Dermatology Association, the rosacea international consensus group (ROSCO) and the acne core outcomes research network (ACORN). He has been an associate editor of the Journal of the American Academy of Dermatology and the British Journal of Dermatology. Over the past 3 decades, Dr. Tan has authored/co-authored more than 100 peer-reviewed publications.

Plenary Session 1: 10:15 AM - 10:35 AM

NOV 2 (Thu)

The tale of oral isotretinoin: From miracle to maligned to managed

Isotretinoin, a synthetic retinoid developed by Hoffman la Roche (Basel Switzerland) and patented in 1969, was initially intended for use as a preventive agent for skin cancer. The research at that time was being pursued by Gary Peck, a young researcher with the then National Cancer institute who was studying isotretinoin as a possible lung cancer preventive agent and in various cutaneous keratinizing disorders including psoriasis, ichthyosis and Darier’s disease. In a presentation to the dermatology research group at the University of Pennsylvania – Albert Kligman asked him about the effects on acne. This question spurred him to initiate a small clinical trial on severe recalcitrant nodular acne in 1977. In that study the clinical effect was termed miraculous. Despite known issues with teratogenicity, it was FDA approved in 1982. Since then, while being the salvation for acne sufferers globally it has also been the target of misinformation, litigation and increasing scrutiny from the public, clinicians and regulatory authorities. In 2006, the prescribing of isotretinoin was even more tightly regulated and managed in the USA with introduction of iPledge. Nevertheless, it became and remains the unsurpassed standard of acne efficacy to the present day, 41 years after approval. In this presentation, I discuss the development of oral isotretinoin with acknowledgment to the people pivotal to its emergence and its ongoing evolution.

Plenary Session 1: 11:15 AM - 11:25 AM

NOV 2 (Thu)

Q & A